WASHINGTON – The Centers for Medicare & Medicaid Services is implementing the Substance Access Beneficiary Engagement Incentive, a new initiative focused on cost-effective care delivery and payment. This incentive is being introduced under existing Innovation Center model authorities and is consistent with federal laws, including the 2018 Agriculture Improvement Act. While CMS is facilitating this program, the agency stated that this does not constitute a Medicare coverage change, and CMS will not pay for or reimburse providers for these products.
The program includes several program integrity safeguards to protect patients and ensure appropriate use. These requirements include strict product standards, physician oversight, and restrictions on marketing intended to induce beneficiary selection. Furthermore, those responsible for procurement must comply with specific regulations governing financial arrangements. CMS clarified that it does not make any claims regarding the therapeutic value of the products involved in this incentive.
Implementation of the program will be monitored by CMS to evaluate outcomes and test new approaches to healthcare delivery. Detailed information regarding eligibility criteria and program requirements has been made available on the CMS website.
